Visceral leishmaniasis: elimination with existing interventions

被引:86
作者
Matlashewski, Greg [2 ,3 ]
Arana, Byron [2 ]
Kroeger, Axel [2 ]
Battacharya, Sujit [2 ,4 ]
Sundar, Shyam [5 ]
Das, Pradeep [6 ]
Sinha, Prabhat Kumar [6 ]
Rijal, Suman [7 ]
Mondal, Dinesh [8 ]
Zilberstein, Dan [3 ,9 ]
Alvar, Jorge [1 ]
机构
[1] WHO, Dept Control Neglected Trop Dis, CH-1211 Geneva, Switzerland
[2] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland
[3] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada
[4] WHO, SE Asia Off, Delhi, India
[5] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India
[6] Rajandra Mem Res Inst Med Sci, Patna, Bihar, India
[7] BP Koirala Inst Hlth Sci, Dharan, Nepal
[8] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh
[9] Technion Israel Inst Technol, Fac Biol, Haifa, Israel
基金
加拿大健康研究院;
关键词
LIPOSOMAL AMPHOTERICIN-B; SINGLE; AMBISOME; INDIA;
D O I
10.1016/S1473-3099(10)70320-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10 000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance.
引用
收藏
页码:322 / 325
页数:4
相关论文
共 27 条
[11]   Parasite Susceptibility to Amphotericin B in Failures of Treatment for Visceral Leishmaniasis in Patients Coinfected with HIV Type 1 and Leishmania infantum [J].
Lachaud, Laurence ;
Bourgeois, Nathalie ;
Plourde, Marie ;
Leprohon, Philippe ;
Bastien, Patrick ;
Ouellette, Marc .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (02) :E16-E22
[12]   Visceral Leishmaniasis Elimination Programme in India, Bangladesh, and Nepal: Reshaping the Case Finding/Case Management Strategy [J].
Mondal, Dinesh ;
Singh, Shri Prakash ;
Kumar, Narendra ;
Joshi, Anand ;
Sundar, Shyam ;
Das, Pradeep ;
Siddhivinayak, Hirve ;
Kroeger, Axel ;
Boelaert, Marleen .
PLOS NEGLECTED TROPICAL DISEASES, 2009, 3 (01)
[13]   Unresponsiveness to AmBisome in some Sudanese patients with kata-azar [J].
Mueller, Marius ;
Ritmeijer, Koert ;
Balasegaram, Manica ;
Koummuki, Youssif ;
Santana, Muriel Ramirez ;
Davidson, Robert .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2007, 101 (01) :19-24
[14]   Advances in leishmaniasis [J].
Murray, HW ;
Berman, JD ;
Davies, CR ;
Saravia, NG .
LANCET, 2005, 366 (9496) :1561-1577
[15]   Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India [J].
Olliaro, P. ;
Sundar, S. .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2009, 14 (01) :88-92
[16]   Antifungal resistance in pathogenic fungi [J].
Perea, S ;
Patterson, TF .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (09) :1073-1080
[17]  
Sharma Umakant, 2008, Journal of Vector Borne Diseases, V45, P255
[18]   Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations [J].
Sundar, S ;
Mehta, H ;
Suresh, AV ;
Singh, SP ;
Rai, M ;
Murray, HW .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :377-383
[19]   Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study [J].
Sundar, S ;
Jha, TK ;
Thakur, CP ;
Mishra, M ;
Singh, VP ;
Buffels, R .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) :800-804
[20]   Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: A multicenter study [J].
Sundar, S ;
Jha, TK ;
Thakur, CP ;
Mishra, M ;
Singh, VP ;
Buffels, R .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2002, 66 (02) :143-146